Home LiteratureArticle Details
PMID: 3306422 Published · ppublish English Clinical Trial Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection.

Nephron ·Vol. 46 Suppl 1 ·1987-00-00 ·Pages 19-33

Fung JJ, Demetris AJ, Porter KA, Iwatsuki S, Gordon RD, Esquivel CO, Jaffe R, Tzakis A, Shaw BW, Starzl TE

Abstract

OKT3 monoclonal antibody therapy was added to preexisting baseline immunosuppressive treatment with ciclosporin and steroids to treat rejection in 52 recipients of cadaveric livers and 10 recipients of cadaveric kidneys. Rejection was controlled in 75% of patients treated, often after high-dose steroid therapy had failed. Rejection recurred during the 17-month follow-up period, after completion of OKT3, in only 25% of the patients who had responded. The safety and effectiveness of this monoclonal therapy, added to ciclosporin and steroids, has been established in this study.

MeSH Terms
Adolescent Adult Antibodies, Monoclonal/administration & dosage Child Child, Preschool Clinical Trials as Topic Cyclosporins/administration & dosage Drug Therapy, Combination Graft Rejection Humans Infant Kidney Transplantation Liver/pathology Liver Transplantation Middle Aged Steroids/administration & dosage
Chemicals
Antibodies, Monoclonal Cyclosporins Steroids
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Fung J J
Demetris A J
Porter K A
Iwatsuki S
Gordon R D
Esquivel C O
Jaffe R
Tzakis A
Shaw B W
Starzl T E
References (38)
38 references, click to expand
  1. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.
    Transplantation. 1981 Dec;32(6):535-9 PMID: 7041358
  2. RENAL FAILURE IN PATIENTS WITH CIRRHOSIS OF THE LIVER. I. CLINICAL AND PATHOLOGIC CHARACTERISTICS.
    Am J Med. 1965 Aug;39:184-98 PMID: 14320684
  3. THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE.
    Surg Gynecol Obstet. 1963 Oct;117:385-95 PMID: 14065716
  4. Renal failure in children with hepatic failure undergoing liver transplantation.
    J Pediatr. 1986 Mar;108(3):393-8 PMID: 3512808
  5. Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation.
    Semin Liver Dis. 1985 Nov;5(4):357-68 PMID: 3909430
  6. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants.
    N Engl J Med. 1985 Aug 8;313(6):337-42 PMID: 2861567
  7. A reappraisal of the effects of monoclonal antibodies directed at T cell differentiation antigens.
    Transplantation. 1984 Dec;38(6):720-6 PMID: 6239416
  8. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection.
    Transplantation. 1984 Dec;38(6):695-701 PMID: 6390834
  9. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation.
    Surg Gynecol Obstet. 1967 Feb;124(2):301-8 PMID: 4163340
  10. Survival of skin heterografts under treatment with antilymphocytic serum.
    Lancet. 1968 Jun 1;1(7553):1174-6 PMID: 4172292
  11. Orthotopic homotransplantation of the human liver.
    Ann Surg. 1968 Sep;168(3):392-415 PMID: 4877589
  12. Modification of established rejection of canine kidney and liver homografts with antilymphocyte gamma-G globulin.
    Surgery. 1969 Sep;66(3):546-9 PMID: 4896070
  13. Use of antithymocyte globulin in human heart transplantation.
    Circulation. 1972 May;45(5 Suppl 1):I147-53 PMID: 4554349
  14. Radionuclides in renal transplantation.
    J Nucl Med. 1972 Nov;13(11):795-800 PMID: 4562617
  15. Continuous cultures of fused cells secreting antibody of predefined specificity.
    Nature. 1975 Aug 7;256(5517):495-7 PMID: 1172191
  16. Seven years' experience with antilymphoblast globulin for renal transplantation from cadaver donors.
    Ann Surg. 1976 Sep;184(3):352-68 PMID: 786192
  17. Cyclosporin A in patients receiving renal allografts from cadaver donors.
    Lancet. 1978 Dec 23-30;2(8104-5):1323-7 PMID: 82836
  18. Fifteen years of clinical liver transplantation.
    Gastroenterology. 1979 Aug;77(2):375-88 PMID: 376395
  19. Monoclonal antibodies defining distinctive human T cell surface antigens.
    Science. 1979 Oct 19;206(4416):347-9 PMID: 314668
  20. Use of antithymocyte globulin for reversal of acute allograft rejection.
    Transplantation. 1979 Dec;28(6):461-4 PMID: 390784
  21. OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.
    J Immunol. 1980 Jun;124(6):2708-13 PMID: 6966296
  22. The use of cyclosporin A and prednisone in cadaver kidney transplantation.
    Surg Gynecol Obstet. 1980 Jul;151(1):17-26 PMID: 6992310
  23. Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells?
    Proc Natl Acad Sci U S A. 1981 Mar;78(3):1805-8 PMID: 6165018
  24. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts.
    N Engl J Med. 1981 Aug 6;305(6):308-14 PMID: 6454075
  25. Effects of antithymocyte globulin on cytomegalovirus infection in renal transplant recipients.
    Transplantation. 1981 Feb;31(2):143-5 PMID: 6266084
  26. Successful liver transplantation from crossmatch-positive donors.
    Transplant Proc. 1981 Mar;13(1 Pt 1):286-8 PMID: 7022840
  27. Evaluation in primate renal allograft recipients of monoclonal antibody to human T-cell subclasses.
    Transplant Proc. 1981 Mar;13(1 Pt 1):499-503 PMID: 7022882
  28. OKT3 monoclonal antibody inhibits cytotoxic T lymphocyte mediated cell lysis.
    Int J Immunopharmacol. 1981;3(3):183-6 PMID: 6457003
  29. Mechanism of T cell activation: role and functional relationship of HLA-DR antigens and interleukins.
    Immunol Rev. 1982;63:73-110 PMID: 6804370
  30. Variable convalescence and therapy after cadaveric renal transplantation under cyclosporin A and steroids.
    Surg Gynecol Obstet. 1982 Jun;154(6):819-25 PMID: 7043758
  31. Antigen recognition by human T lymphocytes is linked to surface expression of the T3 molecular complex.
    Cell. 1982 Oct;30(3):735-43 PMID: 6982759
  32. Tolerance of T-cell clones is associated with membrane antigen changes.
    Nature. 1983 Jun 16-22;303(5918):625-7 PMID: 6343888
  33. OKT8 antibody inhibits OKT3-induced IL 2 production and proliferation in OKT8+ cells.
    J Immunol. 1983 Nov;131(5):2356-61 PMID: 6605385
  34. Antithymocyte globulin as the primary treatment for renal allograft rejection.
    Transplantation. 1983 Nov;36(5):587-9 PMID: 6356523
  35. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level.
    J Immunol. 1984 Jul;133(1):123-8 PMID: 6327821
  36. Human T lymphocyte activation by monoclonal antibodies; OKT3, but not UCHT1, triggers mitogenesis via an interleukin 2-dependent mechanism.
    J Immunol. 1984 Jul;133(1):129-32 PMID: 6327822
  37. Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line.
    J Exp Med. 1984 Nov 1;160(5):1284-99 PMID: 6208306
  38. Treatment of acute graft-versus-host disease with monoclonal antibody OKT3. Clinical results and effect on circulating T lymphocytes.
    Transplantation. 1984 Nov;38(5):469-74 PMID: 6388068
Article Info
Journal
Nephron
Abbr.
Nephron
ISSN
1660-8151
DOI
10.1159/000184431
Published
1987-00-00
Pages
19-33
Language
English
Region
Switzerland
NLM ID
0331777
PMCID
PMC2994552
Subset
IM
Grants
NIDDK NIH HHS · R01 DK029961-19 · United States
NIADDK NIH HHS · AM-29961 · United States
External Links
PubMed source DOI: 10.1159/000184431 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2